Published in Antimicrob Agents Chemother on February 01, 2003
Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev (2010) 4.76
Analysis of cell membrane characteristics of in vitro-selected daptomycin-resistant strains of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (2009) 2.52
Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother (2006) 2.51
Overexpression of genes of the cell wall stimulon in clinical isolates of Staphylococcus aureus exhibiting vancomycin-intermediate- S. aureus-type resistance to vancomycin. J Bacteriol (2006) 2.32
Daptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillin-resistant Staphylococcus aureus with evolving oxacillin susceptibility (the "seesaw effect"). Antimicrob Agents Chemother (2010) 1.98
tcaA inactivation increases glycopeptide resistance in Staphylococcus aureus. Antimicrob Agents Chemother (2004) 1.64
Different bacterial gene expression patterns and attenuated host immune responses are associated with the evolution of low-level vancomycin resistance during persistent methicillin-resistant Staphylococcus aureus bacteraemia. BMC Microbiol (2008) 1.46
Genetic pathway in acquisition and loss of vancomycin resistance in a methicillin resistant Staphylococcus aureus (MRSA) strain of clonal type USA300. PLoS Pathog (2012) 1.44
β-Lactams increase the antibacterial activity of daptomycin against clinical methicillin-resistant Staphylococcus aureus strains and prevent selection of daptomycin-resistant derivatives. Antimicrob Agents Chemother (2012) 1.42
First report of vancomycin-resistant staphylococci isolated from healthy carriers in Brazil. J Clin Microbiol (2005) 1.30
Spontaneous deletion of the methicillin resistance determinant, mecA, partially compensates for the fitness cost associated with high-level vancomycin resistance in Staphylococcus aureus. Antimicrob Agents Chemother (2008) 1.28
A current perspective on daptomycin for the clinical microbiologist. Clin Microbiol Rev (2013) 1.24
In vivo survival of teicoplanin-resistant Staphylococcus aureus and fitness cost of teicoplanin resistance. Antimicrob Agents Chemother (2006) 1.20
Transcriptomic and functional analysis of an autolysis-deficient, teicoplanin-resistant derivative of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (2006) 1.12
Activity of glycopeptides against Staphylococcus aureus infection in a rabbit endocarditis model: MICs do not predict in vivo efficacy. Antimicrob Agents Chemother (2005) 0.96
Vancomycin-intermediate Staphylococcus aureus strains have impaired acetate catabolism: implications for polysaccharide intercellular adhesin synthesis and autolysis. Antimicrob Agents Chemother (2006) 0.95
Daptomycin and tigecycline have broader effective dose ranges than vancomycin as prophylaxis against a Staphylococcus aureus surgical implant infection in mice. Antimicrob Agents Chemother (2012) 0.93
Vancomycin-rifampin combination therapy has enhanced efficacy against an experimental Staphylococcus aureus prosthetic joint infection. Antimicrob Agents Chemother (2013) 0.93
Purification and activity testing of the full-length YycFGHI proteins of Staphylococcus aureus. PLoS One (2012) 0.92
The lantibiotic mersacidin is a strong inducer of the cell wall stress response of Staphylococcus aureus. BMC Microbiol (2008) 0.92
Antibiotic-induced autoactivation of IS256 in Staphylococcus aureus. Antimicrob Agents Chemother (2013) 0.87
Phenotypic and genomic comparisons of highly vancomycin-resistant Staphylococcus aureus strains developed from multiple clinical MRSA strains by in vitro mutagenesis. Sci Rep (2015) 0.83
Strain-specific expression levels of pbp4 exist in isolates of glycopeptide-intermediate Staphylococcus aureus (GISA) and heterogeneous GISA. Antimicrob Agents Chemother (2005) 0.81
Lack of evidence for involvement of hypermutability in emergence of vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother (2003) 0.80
Production of capsular polysaccharide does not influence Staphylococcus aureus vancomycin susceptibility. BMC Microbiol (2013) 0.80
Comparative proteomics-based identification of genes associated with glycopeptide resistance in clinically derived heterogeneous vancomycin-intermediate Staphylococcus aureus strains. PLoS One (2013) 0.78
Vancomycin tolerant, methicillin-resistant Staphylococcus aureus reveals the effects of vancomycin on cell wall thickening. PLoS One (2015) 0.77
Spatio-temporal remodeling of functional membrane microdomains organizes the signaling networks of a bacterium. PLoS Genet (2015) 0.77
The msaABCR operon regulates resistance in vancomycin-intermediate Staphylococcus aureus strains. Antimicrob Agents Chemother (2014) 0.76
Combination prophylactic therapy with rifampin increases efficacy against an experimental Staphylococcus epidermidis subcutaneous implant-related infection. Antimicrob Agents Chemother (2014) 0.76
Polymeric nanofiber coating with tunable combinatorial antibiotic delivery prevents biofilm-associated infection in vivo. Proc Natl Acad Sci U S A (2016) 0.75
Combinatory antibiotic therapy increases rate of bacterial kill but not final outcome in a novel mouse model of Staphylococcus aureus spinal implant infection. PLoS One (2017) 0.75
Draft Genome Sequences of Three Northern German Epidemic Staphylococcus aureus (ST247) Strains Containing Multiple Copies of IS256. Genome Announc (2016) 0.75
A potential role of transposon IS431 in the loss of mecA gene. Sci Rep (2017) 0.75
Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive Infections. Infect Dis Ther (2016) 0.75
Influence of IS256 on genome variability and formation of SCV in Staphylococcus aureus. Antimicrob Agents Chemother (2017) 0.75
Whole genome sequencing of meticillin-resistant Staphylococcus aureus. Lancet (2001) 18.55
Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother (1997) 17.36
Properties of the penicillin-binding proteins of Escherichia coli K12,. Eur J Biochem (1977) 16.26
Structural comparison of three types of staphylococcal cassette chromosome mec integrated in the chromosome in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (2001) 12.65
A new class of genetic element, staphylococcus cassette chromosome mec, encodes methicillin resistance in Staphylococcus aureus. Antimicrob Agents Chemother (2000) 9.84
Novel type of staphylococcal cassette chromosome mec identified in community-acquired methicillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother (2002) 7.98
Bacterial interference caused by autoinducing peptide variants. Science (1997) 7.96
The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med (1999) 7.64
Increase in glutamine-non-amidated muropeptides in the peptidoglycan of vancomycin-resistant Staphylococcus aureus strain Mu50. J Antimicrob Chemother (1998) 5.21
Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50. J Antimicrob Chemother (1998) 4.88
Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Antimicrob Agents Chemother (2002) 4.83
Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus. J Bacteriol (1997) 4.52
Rapid field inversion gel electrophoresis in combination with an rRNA gene probe in the epidemiological evaluation of staphylococci. J Clin Microbiol (1990) 4.08
Exfoliatin-producing strains define a fourth agr specificity group in Staphylococcus aureus. J Bacteriol (2000) 3.70
Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50. Antimicrob Agents Chemother (2000) 3.51
Emergence of heterogeneous intermediate vancomycin resistance in Staphylococcus aureus isolates in the Düsseldorf area. J Antimicrob Chemother (1999) 3.42
Genetic organization of the chromosome region surrounding mecA in clinical staphylococcal strains: role of IS431-mediated mecI deletion in expression of resistance in mecA-carrying, low-level methicillin-resistant Staphylococcus haemolyticus. Antimicrob Agents Chemother (2001) 3.39
The expression in Staphylococcus aureus of cloned DNA encoding methicillin resistance. J Gen Microbiol (1988) 3.34
A membrane enzyme from Staphylococcus aureus which catalyzes transpeptidase, carboxypeptidase, and penicillinase activities. J Biol Chem (1978) 3.07
Identification of the up- and down-regulated genes in vancomycin-resistant Staphylococcus aureus strains Mu3 and Mu50 by cDNA differential hybridization method. Biochem Biophys Res Commun (2000) 3.06
A role in vivo for penicillin-binding protein-4 of Staphylococcus aureus. Eur J Biochem (1981) 2.99
Role of penicillinase plasmids in the stability of the mecA gene in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (1990) 2.93
Inactivated pbp4 in highly glycopeptide-resistant laboratory mutants of Staphylococcus aureus. J Biol Chem (1999) 2.89
Characterization of Staphylococcus aureus isolates with decreased susceptibility to vancomycin and teicoplanin: isolation and purification of a constitutively produced protein associated with decreased susceptibility. J Infect Dis (1992) 2.75
Increased production of penicillin-binding protein 2, increased detection of other penicillin-binding proteins, and decreased coagulase activity associated with glycopeptide resistance in Staphylococcus aureus. Antimicrob Agents Chemother (1997) 2.65
Identification and characterization of SarH1, a new global regulator of virulence gene expression in Staphylococcus aureus. Mol Microbiol (2000) 2.57
Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates. Antimicrob Agents Chemother (2000) 2.48
Cell wall monoglycine cross-bridges and methicillin hypersusceptibility in a femAB null mutant of methicillin-resistant Staphylococcus aureus. J Bacteriol (1997) 2.43
Characterization of passage-selected vancomycin-resistant Staphylococcus aureus strains of diverse parental backgrounds. Antimicrob Agents Chemother (2000) 2.32
Gradual alterations in cell wall structure and metabolism in vancomycin-resistant mutants of Staphylococcus aureus. J Bacteriol (1999) 2.29
Southern hybridization analysis of the mecA deletion from methicillin-resistant Staphylococcus aureus. Biochem Biophys Res Commun (1991) 2.19
Vancomycin-intermediate Staphylococcus aureus in Korea. J Clin Microbiol (2000) 2.16
Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia. Emerg Infect Dis (1999) 2.16
Escherichia coli mutator genes. Trends Microbiol (1999) 2.11
Heterogeneous vancomycin resistance in methicillin-resistant Staphylococcus aureus strains isolated in a large Italian hospital. J Clin Microbiol (2000) 1.98
Presence of Staphylococcus aureus with reduced susceptibility to vancomycin in Germany. Eur J Clin Microbiol Infect Dis (1999) 1.87
Role of penicillin-binding protein 4 in expression of vancomycin resistance among clinical isolates of oxacillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (2001) 1.81
A spectrum of changes occurs in peptidoglycan composition of glycopeptide-intermediate clinical Staphylococcus aureus isolates. Antimicrob Agents Chemother (2001) 1.73
First report of methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in Thailand. J Clin Microbiol (2001) 1.69
Penicillin-binding protein 4 overproduction increases beta-lactam resistance in Staphylococcus aureus. Antimicrob Agents Chemother (1996) 1.55
Suppression of glycopeptide resistance in a highly teicoplanin-resistant mutant of Staphylococcus aureus by transposon inactivation of genes involved in cell wall synthesis. Microb Drug Resist (1998) 1.52
Emergence, mechanism, and clinical implications of reduced glycopeptide susceptibility in Staphylococcus aureus. Eur J Clin Microbiol Infect Dis (2001) 1.48
Analysis of vancomycin population susceptibility profiles, killing activity, and postantibiotic effect against vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother (1999) 1.46
Clinical isolate of vancomycin-heterointermediate Staphylococcus aureus susceptible to methicillin and in vitro selection of a vancomycin-resistant derivative. Antimicrob Agents Chemother (2001) 1.37
Inactivation of the methicillin resistance gene mecA in vancomycin-resistant Staphylococcus aureus. Microb Drug Resist (1999) 1.37
Staphylococcus aureus and Micrococcus luteus peptidoglycan transglycosylases that are not penicillin-binding proteins. J Bacteriol (1984) 1.34
Outbreak of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in a Parisian hospital. J Clin Microbiol (2000) 1.33
Genetic basis of methicillin resistance in Staphylococcus aureus. Cell Mol Life Sci (1999) 1.21
Preliminary analysis of the genetic basis for vancomycin resistance in Staphylococcus aureus strain Mu50. J Antimicrob Chemother (2002) 1.16
Increased glycan chain length distribution and decreased susceptibility to moenomycin in a vancomycin-resistant Staphylococcus aureus mutant. Antimicrob Agents Chemother (2002) 1.10
Co-elimination of mec and spa genes in Staphylococcus aureus and the effect of agr and protein A production on bacterial adherence to cell monolayers. J Med Microbiol (1993) 1.06
Effects of penicillin-binding protein 4 overproduction in Staphylococcus aureus. Microb Drug Resist (1996) 0.99
Transcription analysis of the Staphylococcus aureus gene encoding penicillin-binding protein 4. J Bacteriol (1997) 0.95
Ribosomally synthesized and post-translationally modified peptide natural products: overview and recommendations for a universal nomenclature. Nat Prod Rep (2013) 5.38
Interaction between two murein (peptidoglycan) synthases, PBP3 and PBP1B, in Escherichia coli. Mol Microbiol (2006) 1.86
Lytic activity of recombinant bacteriophage phi11 and phi12 endolysins on whole cells and biofilms of Staphylococcus aureus. Appl Environ Microbiol (2006) 1.62
Role of insertion elements and yycFG in the development of decreased susceptibility to vancomycin in Staphylococcus aureus. Int J Med Microbiol (2007) 1.57
Mutations are involved in emergence of aminoglycoside-induced small colony variants of Staphylococcus aureus. Int J Med Microbiol (2003) 1.48
In vitro murein peptidoglycan synthesis by dimers of the bifunctional transglycosylase-transpeptidase PBP1B from Escherichia coli. J Biol Chem (2005) 1.48
Mersacidin eradicates methicillin-resistant Staphylococcus aureus (MRSA) in a mouse rhinitis model. J Antimicrob Chemother (2004) 1.35
Cell wall composition and decreased autolytic activity and lysostaphin susceptibility of glycopeptide-intermediate Staphylococcus aureus. Antimicrob Agents Chemother (2004) 1.35
Analysis of the matrix-assisted laser desorption ionization-time of flight mass spectrum of Staphylococcus aureus identifies mutations that allow differentiation of the main clonal lineages. J Clin Microbiol (2013) 1.34
The beta-lactam-resistance modifier (-)-epicatechin gallate alters the architecture of the cell wall of Staphylococcus aureus. Microbiology (2007) 1.30
Dissecting structural and functional diversity of the lantibiotic mersacidin. Chem Biol (2009) 1.25
NMR study of mersacidin and lipid II interaction in dodecylphosphocholine micelles. Conformational changes are a key to antimicrobial activity. J Biol Chem (2003) 1.25
An elevated mutation frequency favors development of vancomycin resistance in Staphylococcus aureus. Antimicrob Agents Chemother (2002) 1.24
Construction of an expression system for site-directed mutagenesis of the lantibiotic mersacidin. Appl Environ Microbiol (2003) 1.20
Production of the novel two-peptide lantibiotic lichenicidin by Bacillus licheniformis DSM 13. PLoS One (2009) 1.14
Increased glycan chain length distribution and decreased susceptibility to moenomycin in a vancomycin-resistant Staphylococcus aureus mutant. Antimicrob Agents Chemother (2002) 1.10
Role of the single regulator MrsR1 and the two-component system MrsR2/K2 in the regulation of mersacidin production and immunity. Appl Environ Microbiol (2002) 1.07
Mode of action of human beta-defensin 3 against Staphylococcus aureus and transcriptional analysis of responses to defensin challenge. Int J Med Microbiol (2008) 1.05
GNA33 from Neisseria meningitidis serogroup B encodes a membrane-bound lytic transglycosylase (MltA). Eur J Biochem (2002) 1.05
Native graS mutation supports the susceptibility of Staphylococcus aureus strain SG511 to antimicrobial peptides. Int J Med Microbiol (2009) 1.05
Biological characterization of novel inhibitors of the gram-positive DNA polymerase IIIC enzyme. Antimicrob Agents Chemother (2005) 1.02
Influence of ciprofloxacin and vancomycin on mutation rate and transposition of IS256 in Staphylococcus aureus. Int J Med Microbiol (2010) 1.00
Influence of proteins Bsp and FemH on cell shape and peptidoglycan composition in group B streptococcus. Microbiology (2002) 1.00
Living with an imperfect cell wall: compensation of femAB inactivation in Staphylococcus aureus. BMC Genomics (2007) 0.97
The lantibiotic mersacidin is an autoinducing peptide. Appl Environ Microbiol (2006) 0.97
Detection of astrovirus in premature infants with necrotizing enterocolitis. Pediatr Infect Dis J (2008) 0.95
Functional analysis of a PcsB-deficient mutant of group B streptococcus. FEMS Microbiol Lett (2003) 0.95
The flavoprotein MrsD catalyzes the oxidative decarboxylation reaction involved in formation of the peptidoglycan biosynthesis inhibitor mersacidin. J Bacteriol (2002) 0.93
Purification and activity testing of the full-length YycFGHI proteins of Staphylococcus aureus. PLoS One (2012) 0.92
The lantibiotic mersacidin is a strong inducer of the cell wall stress response of Staphylococcus aureus. BMC Microbiol (2008) 0.92
Marine myxobacteria as a source of antibiotics--comparison of physiology, polyketide-type genes and antibiotic production of three new isolates of Enhygromyxa salina. Mar Drugs (2010) 0.87
Antibiotic-induced autoactivation of IS256 in Staphylococcus aureus. Antimicrob Agents Chemother (2013) 0.87
Expression of the lantibiotic mersacidin in Bacillus amyloliquefaciens FZB42. PLoS One (2011) 0.86
Revisiting the genomes of the Staphylococcus aureus strains NCTC 8325 and RN4220. Int J Med Microbiol (2012) 0.86
Improved synthesis of antibacterial 3-substituted 6-anilinouracils. Bioorg Med Chem Lett (2008) 0.84
Salimabromide: unexpected chemistry from the obligate marine myxobacterium Enhygromxya salina. Chemistry (2013) 0.84
Understanding the physiology and adaptation of staphylococci: a post-genomic approach. Int J Med Microbiol (2007) 0.84
Salimyxins and enhygrolides: antibiotic, sponge-related metabolites from the obligate marine myxobacterium Enhygromyxa salina. Chembiochem (2013) 0.82
Diversification of clonal complex 5 methicillin-resistant Staphylococcus aureus strains (Rhine-Hesse clone) within Germany. J Clin Microbiol (2012) 0.80
Production of capsular polysaccharide does not influence Staphylococcus aureus vancomycin susceptibility. BMC Microbiol (2013) 0.80
Genome sequence of Staphylococcus aureus VC40, a vancomycin- and daptomycin-resistant strain, to study the genetics of development of resistance to currently applied last-resort antibiotics. J Bacteriol (2012) 0.79
Pulsed-field gel electrophoresis of Staphylococcus aureus isolates from atopic patients revealing presence of similar strains in isolates from children and their parents. J Clin Microbiol (2007) 0.78
New DNA polymerase IIIC inhibitors: 3-subtituted anilinouracils with potent antibacterial activity in vitro and in vivo. ChemMedChem (2008) 0.76